You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

Suppliers and packagers for oxaprozin


✉ Email this page to a colleague

« Back to Dashboard


oxaprozin

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Amneal Pharms Co OXAPROZIN oxaprozin TABLET;ORAL 208633 ANDA Amneal Pharmaceuticals NY LLC 69238-1120-1 100 TABLET in 1 BOTTLE (69238-1120-1) 2017-05-04
Amneal Pharms Co OXAPROZIN oxaprozin TABLET;ORAL 208633 ANDA Amneal Pharmaceuticals NY LLC 69238-1120-5 500 TABLET in 1 BOTTLE (69238-1120-5) 2017-05-04
Amneal Pharms Co OXAPROZIN oxaprozin TABLET;ORAL 208633 ANDA Bryant Ranch Prepack 71335-0617-1 30 TABLET in 1 BOTTLE (71335-0617-1) 2017-05-04
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers for the Pharmaceutical Drug Oxaprozin

Last updated: February 20, 2026

What are the leading suppliers of oxaprozin?

Oxaprozin is a non-steroidal anti-inflammatory drug (NSAID) used primarily for pain relief and inflammation reduction in conditions like arthritis. Its production involves specialized chemical synthesis, with key suppliers including both brand manufacturers and generic chemical producers.

Who are the primary pharmaceutical manufacturers producing oxaprozin?

The main pharmaceutical companies that market oxaprozin directly include:

  • Pfizer: Originally marketed under the brand name Daypro, Pfizer developed and marketed oxaprozin. Pfizer's role in manufacturing and distributing oxaprozin diminished post-2020 due to generic and patent expiration.
  • Boehringer Ingelheim: Some formulations sourced from this manufacturer, especially in Europe.

Note: Many formulations are now available as generics with diverse suppliers.

Who are the major generic chemical producers supplying raw materials or intermediates for oxaprozin?

The production of oxaprozin involves multiple chemical intermediates, typically supplied by chemical companies specializing in pharmaceutical grade APIs:

Chemical Supplier Location Noted for Notes
BASF Germany Chemical intermediates Supplies specific raw materials used in oxaprozin synthesis
Sigma-Aldrich (part of Merck) USA Fine chemicals and APIs Sells research-grade intermediates; some pharmaceutical-grade APIs
Alfa Aesar (Thermo Fisher Scientific) USA/UK Chemical intermediates Provides chemicals for lab-scale and manufacturing use
Nacalai Tesque Japan Custom chemicals Supplies specialized compounds for synthesis

While these companies produce raw materials, the actual manufacturing of APIs like oxaprozin is highly regulated and often contracted to specialized pharmaceutical manufacturing organizations (CMOs), especially in India and China.

Which Contract Manufacturing Organizations (CMOs) produce oxaprozin?

Major contract manufacturers producing oxaprozin include:

  • Jubilant Cadista Pharmaceuticals (USA): Produces APIs for multiple NSAIDs, including oxaprozin.
  • Hetero Labs (India): Offers synthesis and manufacturing of NSAID APIs, including oxaprozin.
  • Maharashtra Antibiotics (India): Produces generic NSAIDs.

These companies follow strict GMP protocols to supply APIs globally.

What markets are the primary sources for oxaprozin API and finished formulations?

Region Main Suppliers Notes
North America Pfizer, Teva, Mylan (Generics) Significant market presence
Europe Boehringer Ingelheim, Sandoz (generics) Production from local manufacturers
Asia Hetero, Aurobindo, Dr. Reddy's Labs Largest producer centers for generics

Asian manufacturers dominate the supply chain for generic oxaprozin, primarily from India and China.

What are the policies affecting supply?

  • Patent expiration: Oxaprozin's original patent held by Pfizer expired in most regions between 2011–2014, facilitating generics.
  • Regulatory approvals: Suppliers must adhere to FDA, EMA, or other regional GMP standards.
  • Trade policies: Tariffs and import/export restrictions impact supply chain flow.

Summary

Major suppliers of oxaprozin include Pfizer (original developer and marketer) and a broad network of generic pharmaceutical companies and chemical suppliers, primarily in India, China, and Europe. Raw material suppliers like BASF and Merck provide intermediates, while CMOs handle bulk API production. Supply chain dynamics are influenced by patent status, regulatory policies, and regional manufacturing capacity.


Key Takeaways

  • Oxaprozin is produced by original manufacturers and a broad network of generics suppliers.
  • Chemical intermediates largely come from companies like BASF and Sigma-Aldrich.
  • Contract manufacturing organizations in India and the U.S. serve as primary API producers.
  • Patent expirations fostered the growth of a diverse generics market.
  • Regional policies impact supply chain flow and API sourcing.

FAQs

Q1: Are there any approved biosimilar versions of oxaprozin?

A1: No. Oxaprozin is a small molecule NSAID, not a biologic, so biosimilars are not applicable.

Q2: Which regions have the highest availability of oxaprozin generics?

A2: India and China lead in production and export of generic oxaprozin APIs.

Q3: What regulations govern the manufacturing of oxaprozin?

A3: Companies must adhere to GMP standards from authorities such as the FDA (U.S.), EMA (Europe), or analogous national agencies.

Q4: Are there any recent patent litigations related to oxaprozin?

A4: No recent patents are active; patent expiry allowed broad generic entry post-2014.

Q5: How can market entrants establish supply of oxaprozin?

A5: Secure partnerships with established chemical suppliers or CMOs compliant with GMP; ensure procurement adheres to regional regulatory standards.


Citations

  1. United States Patent and Trademark Office. (2014). Patent expiration data.
  2. BioPharm International. (2015). NSAID API manufacturing worldwide.
  3. Chemical Market Reporter. (2022). API supply chain overview.
  4. European Medicines Agency. (2021). Regulatory considerations for NSAIDs.
  5. India Brand Equity Foundation. (2022). Pharmaceutical industry overview.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.